Australian scientists are testing a promising new Covid-19 vaccine technology that could help deliver vaccines to remote areas while ensuring vaccination effectiveness.
Scientists from the University of Queensland, Australia are collaborating with the country’s biotech company Vaxxas to conduct a trial of a technology for injecting a Covid-19 vaccine without using a needle.
Dr. David Muller with the high-density biopatch. Photo: Hung Vu. The technology allows researchers to use a bio-patch containing a dry layer of vaccine and then apply pressure from the injection device to deliver the vaccine into cells below the surface of the skin. Besides not using needles, this technology being tested on mice also has the outstanding advantage that it does not need to be stored in the cold chain. According to Dr David Muller, Australia’s leading virologist who was involved in the development of the new injection method, the Covid-19 vaccine delivered via a high-density biopatch induces a better immune response and faster. This technology has also shown to be more effective against dangerous variants of the current SARS-CoV-2 virus. What is unique about this single-dose vaccine technology, says Dr. Muller, is that it can help accelerate global vaccine coverage efforts, especially in low-income countries and regions of the world. remote areas. Tests to date have shown that when coated on a dry patch, the vaccine remains stable for at least 30 days in an environment of 25 degrees Celsius and 1 week if it is at 40 degrees Celsius. Using this technology, vaccines will not need to be preserved in complicated and expensive cold chains like today. The developers believe that the applicability of the new technology is very promising. In addition, scientists are also looking for funding to be able to conduct clinical trials on humans in the near future.
You must log in to post a comment.